Bluebird bio on Monday announced that it has signed a five-year, term loan deal with Hercules Capital, providing the biotech with up to $175 million in debt financing to support its launch activities for sickle cell disease gene therapy Lyfgenia.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,